Stem Cell Therapeutics plummets on failed Phase IIb stroke trial
This article was originally published in Scrip
Executive Summary
Stem Cell Therapeutics' NTx-265 has failed to meet its primary endpoint in a Phase II stroke trial, top-line results show. The Canadian company's share price fell by around 75% on the news to settle at CDN$0.09 ($0.08) on the Toronto Venture Exchange yesterday.